Skip to main content
CTOS 2025 Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.

Soft Tissue Tumors

(P 395) ERIBULIN IN RECURRENT PRETREATED METASTATIC SOFT TISSUE SARCOMA. A CANADIAN SARCOMA RESEARCH AND CLINICAL COLLABORATION (CANSARCC) REAL WORLD ANALYSIS

    Author(s)

  • Carlos Diego H Lopes, MD (he/him/his)

    Medical Oncologist, Clinical and Research Fellow
    Princess Margaret Cancer Centre, Mount Sinai Hospital, University of Toronto
    Toronto, Ontario, Canada

    • Co-Author(s)

  • HP

    Hagit Peretz Soroka, Ph.D. (she/her/hers)

    CanSaRCC Program Manager, Senior Scientific Associate
    Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) - Princess Margaret Cancer Centre
    Toronto, Ontario, Canada

  • MJ

    Michelle A. Jude Michael, BSc (she/her/hers)

    Research Student
    University Health Network, Toronto, Canada
    Toronto, Ontario, Canada

  • Xiaolan Feng, MD

    Clinical Associate Professor
    University of Calgary
    Calgary, Alberta, Canada

  • Amirrtha Srikanthan, Dr

    Medical Oncologist
    Department of Medical Oncology, The Ottawa Hospital, Ottawa, ON, Canada
    Ottawa, Ontario, Canada

  • Christopher Lemieux, Dr

    Faculty
    Service d'Hémato-oncologie, CHU de Québec-Université Laval, Québec, Canada
    Quebec, Quebec, Canada

  • Luigi Russo, B.A.

    Clinical Research Coordinator
    BC Cancer Agency
    Kelowna, British Columbia, Canada

  • Abdulazeez Salawu, MD PhD

    Medical Oncologist
    Princess Margaret and Mt Sinai Hospitals
    Toronto, Ontario, Canada

  • EL

    Evelyn Li

    Research Assistant
    Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada
    Calgary, Alberta, Canada

  • Nikol Kuleshov, Medical Student

    Clerck
    Service d'hémato-oncologie, CHU de Québec - Université Laval, Québec, Canada
    Quebec, Quebec, Canada

  • HS

    Hugo Styves, N/A, Dr

    Research Assistant
    Division of Hematology, Oncology and Cellular Therapy, Department of Medicine, Hôpital Maisonneuve-Rosemont, Université de Montréal, Montreal, Quebec, Canada.
    Quebec, Quebec, Canada

  • KM

    Kayla Marritt, MD MSc BScH

    University of Saskatchewan
    Saskatoon, Saskatchewan, Canada

  • BM

    Billal Marwa, Dr

    Division of Medical Oncology, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan, Canada
    Saskatoon, Saskatchewan, Canada

  • Yusra Kassim, Dr (she/her/hers)

    Clinical Research Associate
    Department of Medical Oncology, The Ottawa Hospital, Ottawa, ON, Canada.
    Ottawa, Ontario, Canada

  • Jonathan Noujaim, MD (he/him/his)

    Associate Professor of Medicine
    Hôpital Maisonneuve-Rosemont and McGill University Health Center
    Montreal, Quebec, Canada

  • Olga Vornicova, Dr

    Clinical Assistant Professor
    Division of Medical Oncology, BC Cancer, University of British Columbia, Vancouver, British Columbia, Canada.
    Victoria, British Columbia, Canada

  • Abha A A. Gupta, Dr (she/her/hers)

    Medical Oncologist, Professor of Pediatrics
    Division of Medical Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada and Division of Hematology/Oncology, Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada
    Toronto, Ontario, Canada

  • Albiruni R. A. Razak, MRCP, MBBCh (he/him/his)

    Clinician Investigator
    Princess Margaret Cancer Centre
    Toronto, Ontario, Canada

Objective: Eribulin (E) has demonstrated overall survival (OS) benefit in a phase III trial, particularly in liposarcoma, though the findings had a low fragility index (Braik et al., 2025). We evaluated the real-world effectiveness of E in advanced soft tissue sarcoma (STS).

Methods: Adults (≥18y) with advanced STS who received ≥1 dose of E between April 2014 and March 2023 were included. Clinical data, dose reductions (RE), delays, and ≥G3 adverse events (AE) were retrieved from the multi institutional CanSaRCC Database. Median progression-free survival (PFS) and OS were estimated according to RECIST v1.1 using the Kaplan-Meier and log-rank test. Uni-/multivariate analyses explored outcome predictors.

Results: A total of 168 pts were included. Demographic and clinical data are in Table 1. At a median follow-up of 6.9 months (mo), median OS and PFS were 7.8 (95%CI,6.3–10.3) and 2 (95%CI,1.9–2.4) mo, respectively. A breakdown of PFS and OS for the different subtypes are in Table 1. RE occurred in 43 (25.6%) pts while 10 pts (5.95%) had treatment discontinuation due to AE. The most common ≥G3 AEs were neutropenia (14.9%), anemia (8.9%), and leukopenia (3.6%). On univariate and multivariate analysis, RE and neutropenia were positively associated with PFS; worse ECOG status was associated with inferior OS.

Conclusion: E showed lower OS than previously reported, probably due to use in heavily pretreated pts, supporting real-world validation of trial findings. Toxicity was consistent with prior reports.